A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Latest Information Update: 28 Jun 2024
At a glance
- Drugs Datopotamab deruxtecan (Primary) ; Capecitabine; Eribulin; Gemcitabine; Gemcitabine; Vinorelbine
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms TB-01; TROPION-Breast01
- Sponsors AstraZeneca; AstraZeneca AB
- 04 Jun 2024 Results of Patient-reported outcomes , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 16 May 2024 This study has been Completed in Netherlands, According to European Clinical Trials Database record.
- 02 Apr 2024 According to an AstraZeneca media release, A BLA for datopotamab deruxtecan based on results from this trial has been accepted in the US for the treatment of adult patients with unresectable or mHR-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease. And, The Prescription Drug User Fee Act date, the US FDA action date for its regulatory decision, is during the first quarter of 2025.